Innoviva Financials
INVA Stock | USD 17.55 0.10 0.57% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 13.85 | 9.0266 |
|
|
The financial analysis of Innoviva is a critical element in measuring its lifeblood. Investors should not minimize Innoviva's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Innoviva | Select Account or Indicator |
Understanding current and past Innoviva Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Innoviva's financial statements are interrelated, with each one affecting the others. For example, an increase in Innoviva's assets may result in an increase in income on the income statement.
Please note, the presentation of Innoviva's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Innoviva's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Innoviva's management manipulating its earnings.
Innoviva Stock Summary
Innoviva competes with Oric Pharmaceuticals, Lyra Therapeutics, Inhibrx, ESSA Pharma, and Sensei Biotherapeutics. Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. Innoviva operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US45781M1018 |
CUSIP | 45781M101 88338T104 |
Location | California; U.S.A |
Business Address | 1350 Old Bayshore |
Sector | Pharmaceuticals |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.inva.com |
Phone | 650 238 9600 |
Currency | USD - US Dollar |
Innoviva Key Financial Ratios
Return On Equity | 0.0997 | ||||
Profit Margin | 0.18 % | ||||
Operating Margin | 0.48 % | ||||
Price To Sales | 3.11 X | ||||
Revenue | 310.46 M |
Innoviva Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 724.8M | 999.6M | 926.4M | 1.2B | 1.2B | 1.3B | |
Retained Earnings | (946.4M) | (722.0M) | (456.1M) | (204.9M) | (25.2M) | (26.4M) | |
Other Assets | 293.6M | 657.5M | 425.2M | 198.5M | 228.2M | 131.6M | |
Total Liab | 382.7M | 391.7M | 400.5M | 665.7M | 568.6M | 442.4M | |
Other Current Liab | 5.4M | 6.0M | 5.7M | 31.7M | 17.2M | 12.9M | |
Other Liab | 586K | 219K | 106K | 84.2M | 75.8M | 49.3M | |
Net Debt | 99.0M | 139.0M | 193.1M | 346.8M | 255.6M | 192.9M | |
Accounts Payable | 10K | 66K | 27K | 2.9M | 6.7M | 7.1M | |
Cash | 278.1M | 246.5M | 201.5M | 291.0M | 193.5M | 138.1M | |
Long Term Debt | 377.1M | 385.5M | 394.7M | 540.4M | 446.2M | 321.7M | |
Net Receivables | 79.4M | 93.9M | 110.7M | 64.1M | 84.1M | 88.3M | |
Other Current Assets | 80.4M | 95.6M | 1.4M | 32.5M | 25.9M | 22.6M | |
Total Current Assets | 431.2M | 342.1M | 313.7M | 443.5M | 344.2M | 281.5M | |
Common Stock | 1.0M | 1.0M | 696K | 692K | 633K | 845.9K | |
Inventory | (79.4M) | (93.9M) | (110.7M) | 55.9M | 40.7M | 42.8M | |
Net Tangible Assets | 313.5M | 539.9M | 414.7M | 286.2M | 329.1M | 345.5M | |
Long Term Debt Total | 574.4M | 382.9M | 377.1M | 385.5M | 443.3M | 463.7M | |
Capital Surpluse | 1.3B | 1.3B | 1.3B | 1.3B | 1.1B | 1.1B |
Innoviva Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 18.7M | 18.3M | 19.1M | 15.8M | 19.2M | 15.6M | |
Gross Profit | 261.0M | 336.8K | 391.9M | 317.5M | 261.1M | 274.1M | |
Operating Income | 246.4M | 321.1M | 375.1M | 210.0M | 176.7M | 185.5M | |
Ebit | 217.9M | 303.2M | 426.2M | 302.7M | 213.3M | 223.9M | |
Research Development | 559K | 1.8M | 576K | 41.4M | 33.9M | 48.3M | |
Ebitda | 231.7M | 317.0M | 361.4M | 322.3M | 249.0M | 261.4M | |
Net Income | 157.3M | 224.4M | 265.9M | 213.9M | 179.7M | 188.7M | |
Income Tax Expense | 41.9M | 60.4M | 76.4M | 66.7M | 14.4M | 19.4M | |
Total Revenue | 261.0M | 336.8M | 391.9M | 331.3M | 310.5M | 326.0M | |
Income Before Tax | 232.9M | 354.2M | 445.3M | 286.9M | 194.1M | 203.8M | |
Interest Income | 5.5M | 1.5M | 1.8M | 6.4M | 14.2M | 7.5M | |
Net Interest Income | (13.1M) | (16.8M) | (17.2M) | (9.4M) | (3.0M) | (3.2M) | |
Minority Interest | 11.3M | 33.7M | 69.4M | 103.0M | (6.3M) | 0.0 | |
Tax Provision | 41.9M | 60.4M | 76.4M | 66.7M | 18.3M | 12.4M |
Innoviva Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | 215.7M | (31.6M) | (45.0M) | 89.5M | (97.5M) | (92.7M) | |
Free Cash Flow | 257.4M | 313.1M | 362.5M | 201.7M | 140.7M | 147.7M | |
Depreciation | 13.9M | 13.8M | 13.8M | 19.5M | 35.7M | 37.5M | |
Other Non Cash Items | 5.6M | (42.3M) | (80.4M) | (77.3M) | (59.8M) | (56.8M) | |
Net Income | 191.0M | 293.8M | 368.8M | 220.3M | 179.7M | 188.7M | |
End Period Cash Flow | 278.1M | 246.5M | 201.5M | 291.0M | 193.5M | 138.1M | |
Change To Inventory | (2.0M) | (3.4M) | (664K) | 280K | (12.0M) | (11.4M) | |
Investments | (18.0M) | (314.9M) | 43.7M | (56.6M) | (70.3M) | (66.8M) | |
Change Receivables | (23.7M) | (12.7M) | (14.5M) | (16.8M) | (15.1M) | (15.9M) | |
Net Borrowings | (50.9M) | (230M) | (13.8M) | 87.4M | 78.7M | 40.7M | |
Dividends Paid | 281K | 80K | 11K | 96.3M | 110.7M | 116.3M | |
Change To Netincome | 75.4M | 11.9M | 91.9M | (40.6M) | (36.6M) | (34.7M) |
Innoviva Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Innoviva's current stock value. Our valuation model uses many indicators to compare Innoviva value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Innoviva competition to find correlations between indicators driving Innoviva's intrinsic value. More Info.Innoviva is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about 0.94 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Innoviva is roughly 1.06 . At present, Innoviva's Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Innoviva's earnings, one of the primary drivers of an investment's value.Innoviva Systematic Risk
Innoviva's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Innoviva volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Innoviva correlated with the market. If Beta is less than 0 Innoviva generally moves in the opposite direction as compared to the market. If Innoviva Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Innoviva is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Innoviva is generally in the same direction as the market. If Beta > 1 Innoviva moves generally in the same direction as, but more than the movement of the benchmark.
Innoviva Thematic Clasifications
Innoviva is part of several thematic ideas from Tech Growth to Aggressive Defence. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasToday, most investors in Innoviva Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Innoviva's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Innoviva growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Innoviva December 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Innoviva help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Innoviva. We use our internally-developed statistical techniques to arrive at the intrinsic value of Innoviva based on widely used predictive technical indicators. In general, we focus on analyzing Innoviva Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Innoviva's daily price indicators and compare them against related drivers.
Information Ratio | (0.13) | |||
Maximum Drawdown | 6.8 | |||
Value At Risk | (1.59) | |||
Potential Upside | 1.59 |
Complementary Tools for Innoviva Stock analysis
When running Innoviva's price analysis, check to measure Innoviva's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innoviva is operating at the current time. Most of Innoviva's value examination focuses on studying past and present price action to predict the probability of Innoviva's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innoviva's price. Additionally, you may evaluate how the addition of Innoviva to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |